Last reviewed · How we verify

Caffeine Pill — Competitive Intelligence Brief

Caffeine Pill (Caffeine Pill) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Adenosine receptor antagonist. Area: Neurology / Stimulant.

phase 3 Adenosine receptor antagonist Adenosine receptors (A1, A2A) Neurology / Stimulant Small molecule Live · refreshed every 30 min

Target snapshot

Caffeine Pill (Caffeine Pill) — Rothman Institute Orthopaedics. Caffeine blocks adenosine receptors in the central nervous system, reducing drowsiness and increasing alertness and mental focus.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Caffeine Pill TARGET Caffeine Pill Rothman Institute Orthopaedics phase 3 Adenosine receptor antagonist Adenosine receptors (A1, A2A)
Caffeine citrate oral solution Caffeine citrate oral solution NICHD Global Network for Women's and Children's Health marketed Adenosine receptor antagonist; methylxanthine Adenosine receptors (A1, A2A)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Adenosine receptor antagonist class)

  1. Rothman Institute Orthopaedics · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Caffeine Pill — Competitive Intelligence Brief. https://druglandscape.com/ci/caffeine-pill. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: